Journal of the National Comprehensive Cancer Network : JNCCN最新文献

{"title":"Incorporating the Next Generation of Immunotherapies Into the Treatment of Multiple Myeloma.","authors":"Kevin C Miller, Ross S Firestone, Malin Hultcrantz","doi":"10.6004/jnccn.2026.7004","DOIUrl":"10.6004/jnccn.2026.7004","url":null,"abstract":"<p><p>Immunotherapies have recently changed the treatment landscape of multiple myeloma (MM). CAR T cells and T-cell-redirecting bispecific antibodies (BsAbs) yield impressive responses and extend survival in patients with relapsed/refractory MM. There are now 2 BCMA-directed CAR T-cell products and 4 BsAbs (3 targeting BCMA, 1 targeting GPRC5D) currently approved by the FDA for relapsed/refractory MM, in which they demonstrated considerable efficacy. These drugs are now being evaluated in early treatment settings, including as part of frontline regimens for newly diagnosed MM. Importantly, administration of CAR T-cell therapy and BsAbs necessitate careful attention to unique toxicities, including cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, cytopenias, and heightened infection risk. This review summarizes the current landscape of immunotherapy in MM, including perspectives on sequencing CAR T-cell therapy and BsAbs. It also discusses ongoing clinical trials evaluating immunotherapy in new combinations and treatment contexts. Immunotherapies have become a key component of the MM therapeutic armamentarium and are poised to assume an even larger role in the coming years.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148039086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The NCCN 2026 Annual Conference.","authors":"Renuka Iyer","doi":"10.6004/jnccn.2026.5001","DOIUrl":"https://doi.org/10.6004/jnccn.2026.5001","url":null,"abstract":"","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 Supplement","pages":"1-2"},"PeriodicalIF":16.4,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148059505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Representation in Prostate Cancer Clinical Trials: Needs and Opportunities.","authors":"Hannah D McManus, Daniel J George, Jeffrey W Shevach","doi":"10.6004/jnccn.2026.7002","DOIUrl":"10.6004/jnccn.2026.7002","url":null,"abstract":"<p><p>Prostate cancer (PC) care has undergone a significant transformation in the past decade, leading to unprecedented survival outcomes, particularly for patients with newly diagnosed metastatic disease. However, there is a sizable gap in efficacy and toxicity between PC clinical trial populations and those in the real world. Additionally, there has been a persistent lack of adoption of modern PC therapies, particularly in the metastatic hormone-sensitive PC setting. A key reason for slow adoption, despite robust survival data, is that clinicians feel that their patients are not adequately reflected in clinical trial populations. Key populations that have been underrepresented in PC trials include older adults, individuals with comorbidities, rural populations, and people of non-European ancestry. The lack of these patient populations in modern PC clinical trials impacts the broader adoption of modern therapies, limits our understanding of real-world effectiveness and adverse effect profiles, and hinders the discovery of ancestry-related clinical or pharmacogenomic biomarkers. In this review, we propose multiple strategies to help shape clinical trial populations to better reflect the patients we see in the real world, particularly in later-phase studies.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147985089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Racial Disparities in Lung Cancer Screening Uptake: A Mixed-Methods Study of a Centralized Program.","authors":"Neelima Navuluri, Tiera Lanford-Davey, Govind Krishnan, Abigail Shapiro, Angela B Johnson, Isaretta L Riley, Christopher E Cox, Leah L Zullig, Scott Shofer","doi":"10.6004/jnccn.2026.7001","DOIUrl":"10.6004/jnccn.2026.7001","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer screening (LCS) uptake remains inequitable across the United States, especially among individuals who identify as Black or African American. Synthesized and integrated analyses of quantitative and qualitative studies provide a more thorough understanding of complex facilitators and barriers to LCS uptake among Black veterans.</p><p><strong>Methods: </strong>An explanatory sequential mixed-methods design was used to conduct 1 quantitative and 2 qualitative studies at the Durham Veterans Affairs Healthcare System. Quantitative data from a cross-sectional study of Black and White veterans referred for LCS between July 2013 and August 2021 were integrated with thematic analyses of semistructured interviews with Black veteran patients, primary care providers, and LCS program staff. A content analysis of barriers and facilitators to LCS was guided by Fetters' assessment of coherence to determine the fit of data integration.</p><p><strong>Results: </strong>We integrated data from 4,562 veteran patient electronic health record charts, 32 veteran patient interviews, and 20 health care provider interviews. Areas of confirmation included motivation for screening, patient characteristics and social networks, shared decision-making, and multistep processes for LCS. Areas of discordance included perceived risk, patient-provider trust, rurality, and transportation. Finally, areas of expansion included competing priorities and race, racism, and structural inequities.</p><p><strong>Conclusions: </strong>This study highlights critical areas influencing LCS uptake among Black veterans, as well as where veteran and provider perceptions align-and diverge-from quantitative screening data. The findings underscore the need for implementation strategies that address both individual-level and structural changes to ensure equity in LCS uptake.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2026-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147978518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravenous Patient-Controlled Analgesia Versus Oral Opioids to Maintain Analgesia for Severe Cancer Pain: A Randomized Phase III Trial.","authors":"Rongbo Lin, Lang He, Mingqian Lu, Li Zhuang, Wei Lu, Yunfang Chen, Junli Liu, Shaowei Lin, Shen Zhao, Liyu Su, Xia Lv, Jincai Zhong, Zhichun Zhang, Liyan Gong, Yushuang Luo, Tao Ren, Lei Cao, Jiang Liu, Huichao Zou, Chunxiang Shang, Lichun Cui, Shaojun Chen, Shuqiang Wu, Shanlan Yang, Xiaojuan Zhang, Pengtao Chen, Hong Deng, Yongsheng Zhao, Feng Fu, Bisheng Zhu, Xiaodong Wu, Yiming Bi, Hanxiang An, Tao Sun, Hong Gao, Zhongchao Huo, Jun Liang, Ying Chen, Cheng Huang","doi":"10.6004/jnccn.2025.7476","DOIUrl":"10.6004/jnccn.2025.7476","url":null,"abstract":"<p><strong>Background: </strong>Effective management of severe cancer pain remains challenging. Our phase II study suggested that intravenous patient-controlled analgesia with hydromorphone (IPCA-HM), delivered either as bolus-only or continuous infusion, is superior to oral morphine for patients with severe cancer pain, with bolus-only potentially providing comparable efficacy to infusion while resulting in a lower rate of morphine equivalent dose (MED) escalation. This phase III study aimed to validate these findings.</p><p><strong>Patients and methods: </strong>Patients with solid tumors and severe cancer pain (≥7 at rest on an 11-point Numeric Rating Scale [NRS]) who achieved successful 24-hour IPCA-HM dose-finding were randomized (2:2:1) to bolus-only IPCA-HM (bolus), continuous infusion IPCA-HM (infusion), or oral morphine (oral) for 6 days. The primary outcome was average NRS score over days 1-3 (3DNRS).</p><p><strong>Results: </strong>Of 1,349 patients from 48 oncology centers, 542 received bolus, 540 infusion, and 267 oral. Mean [SD] 3DNRS scores were 2.36 [0.89], 2.26 [0.87], and 2.94 [1.16], respectively. Both IPCA-HM arms were statistically significantly better than the oral arm in 3DNRS scores (bolus vs oral: mean difference, 0.58 [95% CI, 0.42 to 0.74]; infusion vs oral: 0.68 [95% CI, 0.52 to 0.84]; both P<.001). Bolus was noninferior to infusion (mean difference, 0.10 [95% CI, -0.01 to 0.20]; predefined noninferiority margin, 0.3; P<.001), achieving noninferiority in opioid-naïve, but not opioid-tolerant, patients. Median (IQR) total MEDs over days 1-6 were 400 (260-692) mg, 643 (380-1,117) mg, and 867 (540-1,313) mg for the bolus, infusion, and oral arms, respectively. Opioid-related adverse events (all grade 1 or 2) were comparable between the bolus (20.1%) and infusion (23.0%) arms, and both were lower than in the oral arm (33.7%).</p><p><strong>Conclusions: </strong>For severe cancer pain, both IPCA-HM regimens provided statistically significantly better pain relief compared with oral morphine. The bolus regimen achieved noninferior efficacy compared with infusion while requiring lower opioid doses, providing a safe and effective analgesic option.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":"257-264"},"PeriodicalIF":16.4,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147937232","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preoperative Stereotactic Body Radiotherapy for Metastatic Bone Disease With Impending Fracture: A Nonrandomized Clinical Trial.","authors":"Max Vaynrub, Meredith K Bartelstein, Victoria Y Yu, Yoshiya Yamada, Daniel R Gomez, Daniel E Prince, Zhigang Zhang, Stephanie M Lobaugh, Boris A Mueller, Michael B Bernstein, David M Guttmann, Divya Yerramilli, Jonathan T Yang","doi":"10.6004/jnccn.2025.7478","DOIUrl":"10.6004/jnccn.2025.7478","url":null,"abstract":"<p><strong>Background: </strong>Surgical stabilization followed by postoperative radiotherapy (RT) is the standard of care for impending pathologic fractures due to bone metastases. Compared with conventional RT, stereotactic body RT (SBRT) provides more durable tumor control and palliation, but treatment volume constraints often preclude postoperative use. Preoperative SBRT limited to the tumor volume offers a solution by delivering an ablative dose before intraoperative tumor dissemination, but its safety is not established.</p><p><strong>Methods: </strong>We conducted a phase I, nonrandomized clinical trial at a quaternary care cancer center, with accrual between June 2021 and April 2024. Eligible patients (N=38) had pelvic or long bone metastases with impending pathologic fractures requiring surgical stabilization. Patients received preoperative SBRT (27-30 Gy in 3 fractions or 18-24 Gy in 1 fraction) followed by surgical stabilization within 1 week. The primary endpoint was rate of wound complications within 6 weeks after preoperative SBRT and surgical stabilization. Secondary endpoints were rates of tumor recurrence and grade ≥3 treatment-related toxicities within 1 year.</p><p><strong>Results: </strong>A total of 7 patients were excluded due to inability to receive treatment or death prior to the primary endpoint. Thirty-one patients were evaluated at 6 weeks postoperatively, 26 at 3 months, and 16 at 1 year. The median age was 66 years (IQR, 59-71), and 15 (48%) patients were male. At 6 weeks, 2 of 31 patients (6.5%; 95% CI, 0.79-21.4) experienced wound complications. At 3 months, 1 of 26 patients (3.8%; 95% CI, 0.10-19.6) experienced grade ≥3 treatment-related toxicity. At 12 months, 1 of 16 patients (6.3%; 95% CI, 0.16-30.2) had tumor recurrence.</p><p><strong>Conclusions: </strong>Preoperative SBRT is associated with a low risk of wound complications and durable local tumor control. A randomized controlled trial examining its efficacy, potential to facilitate less invasive surgery, and impact on functional outcomes is warranted.</p><p><strong>Clinicaltrials: </strong>gov identifier: NCT05038124.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":"265-270"},"PeriodicalIF":16.4,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13623243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147937257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeted Therapy for Systemic Epstein-Barr Virus-Positive T-Cell Lymphoma of Childhood.","authors":"Jonathan J Holzmann, Michael O'Sullivan, Adrian Charles, Chris Van Vliet, Dong-Anh Khuong-Quang, Michelle Ng, Vasant Chinnabhandar, Shanti Ramachandran, Denitza Mironova, Tina Carter, Rishi S Kotecha, Santosh Valvi","doi":"10.6004/jnccn.2025.7477","DOIUrl":"10.6004/jnccn.2025.7477","url":null,"abstract":"<p><p>Systemic Epstein-Barr virus-positive T-cell lymphoma of childhood (STCLC) is a rare and highly aggressive malignancy with a dismal prognosis and no standard curative treatment. This report describes the first reported case of STCLC in a White child who, after experiencing failure with intensive chemotherapy regimens, achieved a complete response following targeted immunotherapy. Initially, the patient had a rapidly progressive illness with multisystem involvement, presenting as a diagnostic and treatment dilemma due to its rarity. Histomolecular workup was most consistent with a diagnosis of STCLC. Chemotherapy-induced temporary partial response was followed by brisk clinical and radiologic progression. Subsequent immunotherapy resulted in a complete response, which was consolidated with an allogeneic hematopoietic stem cell transplant. The patient currently remains disease-free 3 years later. This case underscores the role of precision medicine in guiding the diagnosis and treatment of rare malignancies. It also highlights the role of immunotherapy as a novel targeted treatment option in STCLC, warranting further investigation.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":""},"PeriodicalIF":16.4,"publicationDate":"2026-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147937227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safely Stopping Premedications in Patients Receiving Paclitaxel: A Randomized Trial.","authors":"Michael Berger, Maryam Lustberg, Paul J Novotny, Nicole Williams, Ashley Pariser Davenport, Robert Wesolowski, Margaret E Gatti-Mays, Jenna Cody, Charles L Loprinzi, Daniel S Childs","doi":"10.6004/jnccn.2025.7475","DOIUrl":"10.6004/jnccn.2025.7475","url":null,"abstract":"<p><strong>Background: </strong>Premedications used to prevent paclitaxel-associated infusion hypersensitivity reactions (iHSRs) can cause undesirable toxicities, such as sleep disturbance and weight gain. Although phase II data suggest that discontinuing premedications after paclitaxel-associated iHSRs may be safe and feasible in select patients without prior iHSRs, no prospective randomized trials have evaluated this approach.</p><p><strong>Patients and methods: </strong>This randomized clinical trial enrolled patients with breast cancer receiving paclitaxel chemotherapy. Those who experienced no iHSRs with the first 2 doses of paclitaxel were randomized to either continue standard premedications (control arm) or to discontinue all premedications (investigational arm). Both arms were followed longitudinally for any subsequent iHSRs requiring parenteral rescue medications. Additionally, changes in weight, drug-related side effects, and quality of life were assessed.</p><p><strong>Results: </strong>A total of 98 patients were randomized; 89 were evaluable (46 in the control arm and 43 in the investigational arm). Only 1 (2.3%) patient in the investigational arm experienced an iHSR, which resolved with rescue medications. No iHSRs occurred in the control arm. The estimated proportion of subjects who experienced a hypersensitivity reaction (exact binomial 95% CI) was 2.3% (95% CI, 0.1%-12.3%) in the investigational arm and 0.0% (95% CI, 0.0%-7.7%) in the control arm. Patients in the investigational arm reported significantly less sleep disruption (0.5 vs 1.7; P=.002) and unwanted appetite increases (1.0 vs 2.5; P=.0018).</p><p><strong>Conclusions: </strong>Discontinuation of premedications after 2 uneventful paclitaxel doses was not associated with a high rate of subsequent iHSRs and resulted in fewer steroid-related side effects. This strategy may reduce unnecessary medication exposure, improve patient experience, and streamline clinical workflows. For patients who do not experience iHSRs during the first 2 paclitaxel treatments, discontinuing premedications appears safe and may improve tolerability.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":"251-256"},"PeriodicalIF":16.4,"publicationDate":"2026-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147857974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired Resistance to Immune Checkpoint Inhibitors Across Tumor Types: A Reconstructed Individual Patient Data Analysis.","authors":"Yago Garitaonaindia, Rikke Andersen, Mario Presti, Marco Donia","doi":"10.6004/jnccn.2025.7142","DOIUrl":"10.6004/jnccn.2025.7142","url":null,"abstract":"<p><strong>Background: </strong>Some patients with cancer who initially benefit from checkpoint inhibitors (CPIs) achieve lasting remission or cure. Acquired resistance to immunotherapy (ARI) refers to disease progression occurring after an initial period of clinical benefit from immune checkpoint blockade. Despite its clinical relevance, the incidence of ARI across tumor types remains largely unknown. We aimed to estimate the overall incidence of ARI across tumor types and examine its association with tumor response.</p><p><strong>Methods: </strong>ARI rates were estimated using a pooled analysis of digitized progression-free survival (PFS) curves from EMA- and FDA-approved phase III trials of CPIs in solid tumors. Only tumors with an overall response rate (ORR) to CPIs ≥20% were considered. PFS ≥6 months was used as a proxy for response to CPIs, based on the Society for Immunotherapy of Cancer (SITC) definition of ARI. Cancer mortality data from GLOBOCAN 2022 were used to estimate the annual incidence of advanced disease across tumor types.</p><p><strong>Results: </strong>Reconstructed pseudo-individual patient data from 15,199 patients across 11 tumor types and 41 phase III trials were included. The estimated pan-cancer weighted rate of ARI was 73.5% (95% CI, 71.6-75.4) at 3 years, ranging from 25.4% in deficient mismatch repair colorectal cancer to 83.1% in squamous esophageal carcinoma; approximately 1,001,815 patients per year may develop ARI globally. RECIST 1.1 complete response (CR), partial response (PR), and stable disease (SD) rates correlated with ARI (CR and PR: ρ = -0.63 and -0.66; P=.044 and .031, respectively; SD: ρ = +0.68; P=.025), and these associations remained consistent after adjusting for tumor type.</p><p><strong>Conclusions: </strong>A considerable proportion of patients who respond to CPIs develop ARI. The variability in ARI incidence across tumor types is explained by the rates of CR, PR, and SD, indicating that the strength of the antitumor response, rather than tumor histology, informs ARI rates.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":" ","pages":"244-250"},"PeriodicalIF":16.4,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147849208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bladder Cancer, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology.","authors":"Thomas W Flaig, Philippe E Spiess, Michael Abern, Yi An, Rick Bangs, Jovan Begovic, Jason Brown, Mark K Buyyounouski, Kevin Chan, Paul Chang, Arnold I Chin, Khurshid A Guru, Harry W Herr, Jean Hoffman-Censits, Hristos Kaimakliotis, Shilajit Kundu, Subodh M Lele, Amy Luckenbaugh, Jonathan Maldonado, Lin Mei, Jeffrey S Montgomery, Mamta Parikh, Anthony Patterson, Charles Peyton, Elizabeth R Plimack, Mark A Preston, Kyle Richards, Steven Seyedin, Arlene O Siefker-Radtke, Tyler Stewart, Debasish Sundi, Umang Swami, Matthew Tollefson, Jonathan L Wright, Carly J Cassara, Bailee Sliker","doi":"10.6004/jnccn.2026.0022","DOIUrl":"10.6004/jnccn.2026.0022","url":null,"abstract":"<p><p>The NCCN Guidelines for Bladder Cancer provide strategies for the diagnosis, treatment, and follow-up of patients with bladder cancer, which is the sixth most common cancer in the United States. Bladder cancer can be divided into 3 categories along a clinical spectrum: (1) non-muscle-invasive bladder cancer; (2) muscle-invasive bladder cancer; and (3) metastatic bladder cancer, with most patients falling into the category of non-muscle-invasive disease. Thus, the selected content featured in this issue specifically covers the clinical presentation and workup of and subsequent management recommendations for non-muscle-invasive bladder cancer.</p>","PeriodicalId":520697,"journal":{"name":"Journal of the National Comprehensive Cancer Network : JNCCN","volume":"24 5","pages":"186-203"},"PeriodicalIF":16.4,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147950671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}